Shots:
- REGENXBIO & Nippon have partnered to develop RGX-121 (Hunter syndrome; FDA’s accelerated approval expected in late 2025, with ongoing rolling BLA filing) & RGX-111 (P-I/II study for Hurler syndrome) in the US & Asia. The closing is expected in Q1’25
- REGENXBIO will get $110M upfront, ~$700M milestones ($40M development & regulatory + $660M sales) plus net-sales-based double-digit royalties in the US & Asia. It also retains all rights on the sale of RGX-121’s PRV, upon approval
- Furthermore, REGENXBIO will handle future development, manufacturing of the drugs for clinical & commercial use (US & Asia) as well as gains right to develop & commercialize them outside of the US & Asia. Nippon will market them in the US & Asia
Ref: Regenxbio | Image: Regenxbio & Nippon Shinyaku
Related News:- AbbVie and Simcere Zaiming Collaborate to Develop SIM0500 for Treating Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
